Literature DB >> 2572265

Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.

E V Sørensen1, O Faergeman, M A Day, H M Snow.   

Abstract

This study was designed to assess the efficacy of xamoterol in 14 patients with mild to moderate heart failure over a period of 18 months. A beneficial effect on exercise capacity and a lowering of heart rate on exercise was sustained, and ejection fraction did not change, although some deterioration may be expected over this length of time in patients with heart failure. Xamoterol is safe and effective, and its benefits are maintained over at least 18 months.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2572265      PMCID： PMC1379886          DOI： 10.1111/j.1365-2125.1989.tb03583.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  2 in total

Review 1.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

2.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245
  2 in total
  2 in total

Review 1.  Long-term studies with xamoterol in heart failure.

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

2.  Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.

Authors:  H Ozaki; H Sato; M Hori; T Matsuyama; K Imai; H Yokoyama; A Kitabatake; M Inoue; T Kamada
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.